Wet Age-related Macular Degeneration
Ophthalmology·MeSH: Macular Degeneration
Prevalence
2000.0 / 100K
Incidence
200.0 / 100K/yr
9 drugs in development·5 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| beovu | Apexigen, Inc. (APGN) |
Phase 3(6)
BLA Filed(1)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| 9mw0211 | Apexigen, Inc. (APGN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Wet Age-related Macular Degeneration?
BioSniper tracks 9 drugs in development for Wet Age-related Macular Degeneration across 5 companies.
How many clinical trials target Wet Age-related Macular Degeneration?
There are 3 clinical trials targeting Wet Age-related Macular Degeneration tracked by BioSniper.
What is the prevalence of Wet Age-related Macular Degeneration?
The estimated prevalence of Wet Age-related Macular Degeneration is approximately 2000.0 per 100,000 population.
Deep-dive into Wet Age-related Macular Degeneration
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis